Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era

References

• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006;107:265–276.
   PubMed Web of Science ®Google Scholar
• Trněný M, Vášová I, Pytlík R, et al. Klin Onkol 2007;20:341–348.
   Google Scholar
• Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019–5026.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• van de Schans SA, Steyerberg EW, Nijziel MR, et al. Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting. Ann Oncol 2009;20:1697–1702.
   PubMed Web of Science ®Google Scholar
• Buske C, Hoster E, Dreyling M, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006;108: 1504–1508.
   PubMed Web of Science ®Google Scholar
• Montoto S, López-Guillermo A, Altés A, et al. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 2004;15:1484–1489.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2:a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555–4562.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Merli M, Passamonti F, et al. Validation of follicular lymphoma international prognostic index 2 (FLIPI 2) score in an independent series of follicular lymphoma patients. Br J Haematol 2010;149:455–457.
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159–2169.
   PubMed Web of Science ®Google Scholar
• Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007;25:390–398.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Novak AJ, Stenson MJ, et al. Intratumoral CD4 + CD25+ regulatory T-cell-mediated suppression of infiltrating CD4 + T cells in B-cell non-Hodgkin lymphoma. Blood 2006;107:3639–3646.
   PubMed Web of Science ®Google Scholar
• Hilchey SP, De A, Rimsza LM, et al. Follicular lymphoma intratumoral CD4 + CD25+ GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8 + CD25- and CD4 + CD25- T cells. J Immunol 2007;178:4051–4061.
   PubMed Web of Science ®Google Scholar
• Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013;38:13–25.
   PubMed Web of Science ®Google Scholar
• Furtado GC, Curotto de Lafaille MA, Kutchukhidze N, et al. Interleukin 2 signaling is required for CD4(+) regulatory T-cell function. J Exp Med 2002;196:851–857.
   PubMed Web of Science ®Google Scholar
• de la Rosa M, Rutz S, Dorninger H, et al. Interleukin-2 is essential for CD4 + CD25+ regulatory T-cell function. Eur J Immunol 2004;34:2480–2488.
   PubMed Web of Science ®Google Scholar
• Rubin LA, Galli F, Greene WC, et al. The molecular basis for the generation of the human soluble interleukin 2 receptor. Cytokine 1990;2:330–336.
   PubMedGoogle Scholar
• Murakami S. Soluble interleukin-2 receptor in cancer. Front Biosci 2004;9:3085–3090.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Grote DM, Ziesmer SC, et al. Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood 2011; 118:2809–2820.
   PubMed Web of Science ®Google Scholar
• Decaudin D, Lepage E, Brousse N, et al. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients–a study of the groupe d’Etude des lymphomes de l’Adulte. J Clin Oncol 1999;17:2499–2505.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328: 1002–1006.
   PubMed Web of Science ®Google Scholar
• Federico M, Clo V, Brugiatelli M, et al. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL. Haematologica 1998;83:800–811.
   Google Scholar
• Prochazka V, Faber E, Raida L, et al. Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009;153:63–66.
   PubMed Web of Science ®Google Scholar
• Colombat P, Biron P, Laporte JP, et al. BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin's lymphomas. Eur J Cancer 1990;26:858.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   Web of Science ®Google Scholar
• Solal-Céligny P, Cahu X, Cartron G. Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?Int J Hematol 2010;92:246–254.
   PubMed Web of Science ®Google Scholar
• Goto N, Tsurumi H, Goto H, et al. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients withdiffuse large B cell lymphoma treated with R-CHOP regimens. Ann Hematol 2012;91:705–714.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Matsuda Y, Takai M, et al. Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma. Anticancer Res 2012;32:5051–5057.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Yokoyama M, Terui Y, et al.Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol 2009;20:526–533.
   PubMed Web of Science ®Google Scholar
• Tomita N, Sakai R, Fujisawa S, et al. SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma. Cancer Sci 2012;103:1518–1523.
   PubMed Web of Science ®Google Scholar
• Yoshizato T, Nannya Y, Imai Y, et al. Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma. Clin Lymphoma Myeloma Leuk 2013;13:410–416.
   PubMed Web of Science ®Google Scholar